Imjudo, an anti-CTLA-4 immuno-cancer drug developed by astrazeneca, is used in combination with Impinzi (durvalumab) as the primary treatment for adult patients with progressive or irresistible hepatocellular carcinoma.
Impinzi is an antibody drug that binds to PD-L1 (cancer cell surface protein). PD-1, a type of immune checkpoint expressed in T cells, helps T cells prevent attacks from normal cells. Cancer cells express PD-L1, a substance that binds to PD-1, deceiving immune cells not to recognize themselves as harmful cells. Impinzi interferes with the interaction between PD-1 and PD-L1, inducing T cells to attack cancer cells.
"Imjudo" is an antibody that selectively blocks the interaction of CD80 and CD86 with CTLA-4 (cytotoxic T lymphocyte-related antigen-4, mainly expressed on the surface of T-lymphocytes and inhibiting T-lymphocyte activity). It improves T-cell activation and proliferation and induces anti-tumor immune responses in T-cells, providing new treatment opportunities for progressive or irreducible hepatocellular carcinoma.